Related Experiment Video
Updated: May 22, 2026
08:56
Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
Published on: November 30, 2022
Meta-analysis: nonsteroidal anti-inflammatory drugs in biliary colic
A Colli1, D Conte, S Della Valle
1Department of Internal Medicine, Ospedale "A. Manzoni", Lecco, Italy.
Alimentary Pharmacology & Therapeutics
|May 1, 2012
Summary
Nonsteroidal anti-inflammatory drugs (NSAIDs) effectively manage biliary colic pain and reduce complications compared to placebo. They are as effective as opioids for pain relief and superior to spasmolytics, establishing NSAIDs as a first-choice treatment.
Area of Science:
- Gastroenterology
- Pharmacology
- Clinical Medicine
Background:
- Biliary colic, a common symptom of gallstones, affects approximately one-third of patients.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently used for biliary pain, but evidence synthesis is lacking.
Purpose of the Study:
- To evaluate the efficacy and safety of NSAIDs for biliary colic.
- To assess pain control and complication reduction benefits of NSAIDs.
- To identify potential harms associated with NSAID use in biliary colic.
Main Methods:
- Systematic review and meta-analysis of randomized clinical trials (RCTs).
- Searched Medline and Embase databases for relevant studies.
- Pooled data using fixed or random-effect models to calculate odds ratios and relative risks.
Main Results:
- Eleven RCTs with 1076 participants were analyzed.
- NSAIDs significantly improved complete pain relief compared to placebo (RR 3.77).
- NSAIDs reduced complications (RR 0.53) and were more effective than spasmolytics for pain (RR 1.47), with similar efficacy to opioids (RR 1.05).
Conclusions:
- NSAIDs are recommended as first-line treatment for biliary colic due to effective pain control and reduced complications.
- NSAID efficacy in pain management is comparable to opioids.
- Limitations include a lack of high-quality RCTs and significant heterogeneity among studies.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:20Cholecystitis
Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...